Related Experiment Videos
[Beta 3-adrenergic receptor agonists--past, present and future]
1Department of Medicine, Fukuchiyama City Hospital, Department of Endocrinology, Diabetes and Metabolism, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|December 4, 2001
Summary
Beta 3-adrenergic receptor (beta 3-AR) agonists show promise for obesity and diabetes treatment. Human variants and visceral fat reduction are key factors influencing their effectiveness.
Area of Science:
- Adrenergic receptor signaling
- Metabolic regulation
- Obesity and diabetes research
Context:
- Beta 3-adrenergic receptors (beta 3-AR) are critical for thermogenesis and lipolysis.
- Early beta 3-AR agonists showed efficacy in rodents but not humans due to structural differences.
- The Trp64Arg variant of the human beta 3-AR gene is linked to obesity and insulin resistance.
Purpose:
- To review the past, present, and future of beta 3-AR agonists for treating obesity and related metabolic disorders.
- To highlight the role of human beta 3-AR variants in drug response.
- To discuss the potential of targeting visceral fat reduction for preventing lifestyle-related diseases.
Summary:
- Beta 3-AR agonists' effectiveness varies between species and is influenced by human genetic variants like Trp64Arg.
- Recent findings show lipolysis differences based on the Trp64Arg mutation and UCP1/beta 3-AR upregulation.
- Reducing visceral fat is crucial for preventing lifestyle-related diseases, increasing interest in human beta 3-AR agonists.
Impact:
- Beta 3-AR agonists offer a potential therapeutic strategy for combating obesity and insulin resistance.
- Understanding genetic variations can personalize treatment approaches for metabolic diseases.
- Targeting beta 3-ARs may lead to novel interventions for managing lifestyle-related diseases through visceral fat reduction.